Diagnosing Vaginal Discharge and Odor

Key Clinical Characteristics

• The Centers for Disease Control and Prevention recommends that you cannot reliably differentiate between STIs based solely on discharge and odor characteristics—microscopy, pH testing, and nucleic acid amplification testing (NAAT) are essential for accurate diagnosis 1, 2
• Bacterial vaginosis is characterized by a homogeneous, thin, white-gray discharge that smoothly coats vaginal walls, a fishy odor, especially after addition of 10% KOH, an elevated pH (>4.5), and clue cells on saline wet mount 1, 2, 3
• Trichomoniasis is characterized by a copious, yellow-green, frothy discharge, a fishy or foul odor, an elevated pH (>4.5), and motile trichomonads on saline wet mount, though sensitivity is only 40-80% 1, 2
• Vulvovaginal candidiasis is characterized by a thick, white, "cottage cheese-like" discharge, no odor, a normal pH (<4.5), and yeasts or pseudohyphae on KOH preparation 1, 4
• Cervicitis from gonorrhea or chlamydia is characterized by a mucopurulent cervical discharge, variable odor, cervical friability, hyperemia, and easily induced bleeding 5, 1

Diagnostic Algorithm

• The American College of Obstetricians and Gynecologists recommends assessing pH using narrow-range pH paper, with a pH >4.5 suggesting bacterial vaginosis or trichomoniasis, and a pH <4.5 suggesting candidiasis 1, 2, 4
• A positive whiff test (10% KOH) suggests bacterial vaginosis or trichomoniasis, while a negative test is more consistent with candidiasis 1, 2, 4
• Microscopy should include saline wet mount to look for clue cells or motile trichomonads, and KOH preparation to look for yeast or pseudohyphae 1, 2, 4
• If microscopy is negative or equivocal, the CDC recommends ordering NAAT for Trichomonas vaginalis, considering Gram stain for definitive BV diagnosis, ordering culture for Candida, and testing for gonorrhea and chlamydia if cervicitis is present or the patient is at risk 2, 5, 1

Critical Pitfalls to Avoid

• The Centers for Disease Control and Prevention recommends never diagnosing based on appearance alone, as clinical appearance of discharge is unreliable for distinguishing between causes 4
• The American College of Obstetricians and Gynecologists recommends not diagnosing BV without clue cells unless confirmed by Gram stain, as this leads to treating the wrong condition 2
• The CDC recommends not relying solely on wet mount for trichomoniasis, as its sensitivity is only 40-80%, and NAAT is the recommended diagnostic method 2
• A thorough physical examination, including visualization of the cervix and perianal area, is essential for accurate diagnosis 5

Management of Green Vaginal Discharge When Cultures Are Negative

Diagnostic Recommendations

• The Centers for Disease Control and Prevention (CDC) recommends obtaining a nucleic‑acid amplification test (NAAT) for Trichomonas vaginalis in any patient with green vaginal discharge, because microscopy and culture detect only 40–80 % of infections; empiric metronidazole should be considered while awaiting results. 6
• Re‑examination of a wet‑mount microscopy slide for motile trichomonads and clue cells remains essential, but diagnostic accuracy depends heavily on the examiner’s skill. 6
• The CDC notes that vaginal culture for T. vaginalis has a sensitivity of only 40–80 % compared with NAAT, so a negative culture does not exclude infection. 6

Point‑of‑Care Tests

• The “whiff” test (addition of 10 % KOH) that produces a fishy odor is indicative of bacterial vaginosis or trichomoniasis and can be used as a bedside screening tool. (American Academy of Family Physicians guidance) 7

Empiric Treatment Strategies

• When the discharge is green, copious, and frothy, the American Academy of Family Physicians (AAFP) advises empiric therapy for trichomoniasis with either a single oral dose of metronidazole 2 g or metronidazole 500 mg taken twice daily for 7 days, even if initial tests are negative. 7
• Simultaneous treatment of sexual partners is recommended to prevent reinfection of trichomoniasis. (AAFP) 7

Follow‑Up and Re‑Evaluation

• Patients should be reassessed if symptoms persist after completing therapy; ongoing symptoms may signal reinfection from an untreated partner or metronidazole‑resistant T. vaginalis. (AAFP) 7

Critical Pitfalls to Avoid

• Do not rely solely on the visual appearance of discharge to determine etiology, as clinical characteristics are unreliable for distinguishing causes. (CDC) 6
• Do not assume that a negative vaginal culture rules out trichomoniasis; NAAT remains the preferred diagnostic modality. (CDC) 6
• Consider the possibility of mixed infections; multiple pathogens may coexist and require combined therapeutic approaches. (CDC) 6

CDC Recommendations for Diagnosis and Management of Vaginal Odor Conditions

Diagnostic Tests

• The “whiff test”—adding 10 % potassium hydroxide to vaginal discharge and detecting an immediate fishy amine odor—is considered pathognomonic for bacterial vaginosis or trichomoniasis. [CDC] 8
• Saline wet‑mount microscopy that reveals clue cells (epithelial cells densely coated with bacteria) confirms bacterial vaginosis; the same preparation can identify motile trichomonads when present. [CDC] 8
• A potassium hydroxide (KOH) preparation of discharge is used to detect yeast forms or pseudohyphae when candidiasis is suspected. [CDC] 8
• When Amsel criteria are borderline, a Gram stain of vaginal fluid provides a definitive diagnosis of bacterial vaginosis. [CDC] 8

Epidemiology

• Bacterial vaginosis is the most common cause of vaginal discharge and malodor, affecting 10 %–35 % of women seen in gynecologic practice. [CDC] 8

Microbiology

• The condition results from a shift away from normal hydrogen‑peroxide‑producing Lactobacillus species toward overgrowth of anaerobic bacteria, chiefly Bacteroides, Mobiluncus, Gardnerella vaginalis, and Mycoplasma hominis. [CDC] 8

Clinical Presentation

• Approximately 50 % of women who meet diagnostic criteria for bacterial vaginosis are asymptomatic. [CDC] 8

Treatment Pitfalls

• Culturing Gardnerella vaginalis is not recommended for diagnosis because the organism is isolated from about 50 % of asymptomatic women and lacks specificity. [CDC] 8
• Male sexual partners should not be treated for bacterial vaginosis, as partner therapy does not prevent recurrence or alter the clinical course. [CDC] 8

Pre‑Procedural Management

• Women should receive treatment for bacterial vaginosis even if asymptomatic before undergoing invasive gynecologic procedures (e.g., surgical abortion, hysterectomy) to lower the risk of postoperative pelvic inflammatory disease and endometritis. [CDC] 8

Guideline Summary for Evaluation of Vaginal Discharge When BV and Candida Tests Are Negative

Diagnostic Test Performance

• Microscopic wet‑mount examination for Trichomonas vaginalis detects only 40–80 % of infections, so a negative result cannot rule out trichomoniasis. (Centers for Disease Control and Prevention – MMWR Recommendations and Reports, 2002) 9
• Culture of T. vaginalis is more sensitive than microscopy but remains less sensitive than nucleic‑acid amplification testing (NAAT). (CDC – MMWR Recommendations and Reports, 2002) 10

Recommended Molecular Testing

• Obtain NAAT for Neisseria gonorrhoeae and Chlamydia trachomatis from a vaginal or cervical swab when mucopurulent cervicitis is suspected, because such infections can present as vaginal discharge. (CDC – MMWR Recommendations and Reports, 2002) 9

Normal (Physiologic) Vaginal Discharge

• Physiologic discharge is typically clear to white, odorless, has a pH < 4.5, and shows only epithelial cells and lactobacilli on microscopy. (CDC – MMWR Recommendations and Reports, 2002) 10

Non‑Infectious Etiologies

• External vulvar inflammation with minimal discharge and no identified pathogens suggests a mechanical, chemical, or allergic irritation (e.g., new soaps, detergents, douches, lubricants, or latex condoms). (CDC – MMWR Recommendations and Reports, 2002) 9

Risks of Empiric Therapy Without Confirmed Diagnosis

• Laboratory testing fails to identify a cause in a minority of women; providing empiric antimicrobial therapy without a confirmed diagnosis contributes to inappropriate antibiotic use. (CDC – MMWR Recommendations and Reports, 2002) 10

Diagnosis and Management of Vaginal Discharge in Adolescents

Epidemiology

• The CDC’s 1998 recommendations identify bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis as the three most common etiologies of vaginal discharge in adolescent patients. 11

Diagnostic Testing

• According to CDC guidance, point‑of‑care evaluation should include preparation of two microscopy slides: (1) a saline wet mount to detect clue cells (indicative of bacterial vaginosis) or motile trichomonads, and (2) a 10 % potassium hydroxide (KOH) preparation to visualize yeast or pseudohyphae for candidiasis. 11

Risk Assessment

• CDC recommendations advise screening all adolescents for sexual activity and assessing risk for sexually transmitted infections, noting that bacterial vaginosis is associated with having multiple sexual partners but can also occur, albeit rarely, in individuals without sexual exposure. 11

Diagnosis and Management of Green Vaginal Discharge in Women Who Meet BV Criteria

Clinical Presentation and Diagnostic Criteria

Diagnostic Testing Recommendations

Treatment Recommendations

Partner Management

Additional Clinical Considerations

Management of Green Vaginal Discharge in Postmenopausal Women

Empiric Antimicrobial Therapy

• In women presenting with green vaginal discharge, a 7‑day course of metronidazole 500 mg orally twice daily yields an 88–95 % cure rate for Trichomonas vaginalis infection and a ≈95 % cure rate for bacterial vaginosis, supporting its use as first‑line empiric therapy while awaiting NAAT results. 13

Sexual Partner Treatment

• Simultaneous treatment of the sexual partner with a single oral dose of metronidazole 2 g is recommended to prevent reinfection, as untreated partners are the most common cause of treatment failure for trichomoniasis. 13

Confirmation of Therapy Completion

• Both the patient and the partner should be confirmed to have completed the prescribed metronidazole regimen before resuming sexual activity, reducing the risk of recurrent infection. 13

Follow‑Up and Test‑of‑Cure Strategy

• Routine follow‑up visits are not required if symptoms resolve after therapy; however, patients should be instructed to return for evaluation if vaginal discharge or odor recurs within two months. 13

Assessment of Predisposing Conditions

• Screening for systemic conditions such as diabetes mellitus and immunosuppression is advised, as these factors increase susceptibility to recurrent vaginal infections, including trichomoniasis, bacterial vaginosis, and candidiasis. 13